Heart Disease :: Barr’s Subsidiary PLIVA Receives Approval for Pravastatin Tablets

Barr Pharmaceuticals, Inc. (NYSE: BRL) and its subsidiary PLIVA d.d. (LSE: PLVD; ZSE: PLVA-R-A) today announced that PLIVA has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market Pravastatin Tablets 10mg, 20mg, and 40mg, the generic version of Bristol-Myers Squibb’s PRAVACHOL(R) (Pravastatin Sodium) Tablets. The Company plans to launch its product immediately. PLIVA has also received tentative approval for its Pravastatin Tablets 80mg strength and plans to launch this strength following the expiration of a competitor’s 180-day generic drug exclusivity period and subsequent final approval of PLIVA’s application.

HIV :: Bristol-Myers Squibb & National AIDS Fund announce World AIDS Day Campaign

Bristol-Myers Squibb Company (NYSE: BMY) in cooperation with the National AIDS Fund today launched the third annual “Light to Unite” campaign in support of World AIDS Day. This year’s “Light to Unite” program shines a light on the devastating impact of the HIV/AIDS epidemic in underserved communities throughout the United States. Bristol-Myers Squibb and the National AIDS Fund are encouraging people across the country to visit http://www.lighttounite.org/ to show their support and to educate themselves and others on emerging HIV/AIDS issues within diverse communities across the U.S.

Breast Cancer :: Aeterna Zentaris – Positive Top Line Phase 1 Results for AN-152 in Gynaecological and Breast Cancers

?terna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today disclosed additional positive top line Phase 1 results for its cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers. Further data showed the compound?s good safety profile and established the maximum tolerated dose (MTD) at 267 mg/m? which will be the recommended dose for a Phase 2 trial. In addition to good safety data, the trial provided a hint of efficacy as disease stabilization and regression of lesions were observed at the 160 mg/m? and 267 mg/m? dose levels.

Disinfectant :: Solvay’s Perestane effective against Clostridium difficile and MRSA

Perestane?, an innovative biocidal product created and developed by Solvay, has been proven to be an effective disinfectant against Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. These so-called ?superbugs? may cause fatal diseases, and the treatment of patients with most current antibiotics is ineffective. Researchers from the University of Leeds and Leeds General Infirmary (United Kingdom) have recently demonstrated that disinfectants commonly used in hospitals fail to eradicate Clostridium difficile from the premises, and may even promote spore formation.

Solvin launches NANOVIN a vinyl nanocomposite smart material

Solvay announces today that its vinyls joint venture in Europe, SolVin, is launching NanoVin?, an innovative nanocomposite combining polyvinyl chloride (PVC) and nanoparticles of clay. This specialty product displays exceptional properties in terms of plasticity, viscosity and flow. These distinctive rheological properties make NanoVin? a so-called ?smart material?, capable of sensing and reacting to changes in its environment (see Notes to the Editors below).

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack